A WHO Summary report on the human papilloma virus, HPV, and cervical cancer statistics in India 2010 reported that nearly 74,000 women die suffering from cervical cancer in India every year. In addition, the report revealed that Indian women lie in the highest risk category for cervical cancer in the world. The vaccines currently available in the market lie in the price bracket of Rs. 2,800 and Rs. 3,300 per dose. Each woman would require three doses which would cost her Rs. 8,400 to Rs. 9,900 depending on which brand of vaccine she uses. The reports posted that poor hygiene and multiple partners are the two main culprits behind cervical cancer. The most common one, which engulfs 1,08,900 affected cases, is HPV and its strains 16 and 18. In men, anal and penile cancer is attributed to the strains of the HPV virus too. Strain 6 and 11, particularly, are known to cause genital warts. Only Gardasil, from Merck & Co., protects against strains 6 and 11 and Cervarix, from GSK, only shields against the 16 and 18 strains of HPV. A study by the Catalan Institute of Oncology, Spain, on cervical cancer and HPV in India posted that if you vaccinate 70% of Indian women (approximately 399,000,000) against the HPV 16 and 18 strains, the cut in lifetime cancer risk was reported to 44%.